Drug Trial Radar · NCT00522951
SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study
Last checked: Nov 19, 2026Latest source record: Aug 28, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
165
Actual
Start
Aug 2007
Primary completion
Aug 2008
Study completion Aug 2008
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Aug 30, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Single (participant)
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is conducted to compare the contrast effect and safety of SH L562BB with ProHance, which has already been approved as a pharmaceutical product of similar indication.
Conditions
- Brain Metastases
Interventions
Gadobutrol (Gadavist, Gadovist, BAY86-4875)Drug
Gadobutrol enhanced MRI (first injection of gadobutrol 0.1 mmol/kg bw, corresponding to a dose of 0.1 mmol/kg bw)
Gadobutrol (Gadavist, Gadovist, BAY86-4875)Drug
Gadobutrol enhanced MRI (second injection of gadobutrol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw)
ProHanceDrug
ProHance enhanced MRI (two injections of gadoteridol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Lesions Detected by Blinded Readers (BR) and InvestigatorTime frame: one day
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Fukuoka, Japan
Site not named
Osaka, Japan
Site not named
Nagoya, Aichi-ken, Japan
Site not named
Matsuyama, Ehime, Japan
Site not named
Kitakyushu, Fukuoka, Japan
Site not named
Sapporo, Hokkaido, Japan
Site not named
Kobe, Hyōgo, Japan
Site not named
Sagamihara, Kanagawa, Japan
Site not named
Yokohama, Kanagawa, Japan
Site not named
Habikino, Osaka, Japan
Site not named
Habikino, Osaka, Japan
Site not named
Sayama, Osaka, Japan
Site not named
Hamamatsu, Shizuoka, Japan
Site not named
Sunto, Shizuoka, Japan
Site not named
Bunkyo-ku, Tokyo, Japan
Site not named
Bunkyo-ku, Tokyo, Japan
Site not named
Chuo-ku, Tokyo, Japan
Site not named
Mitaka, Tokyo, Japan
Site not named
Shinagawa-ku, Tokyo, Japan
Site not named
Yonago, Tottori, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.